172 related articles for article (PubMed ID: 30954331)
1. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
[TBL] [Abstract][Full Text] [Related]
2. Chiral Pool Synthesis, Biological Evaluation and Molecular Docking Studies of C-Furanosidic LpxC Inhibitors.
Dreger A; Kharwb O; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
ChemMedChem; 2019 Apr; 14(8):871-886. PubMed ID: 30801965
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation, and molecular docking studies of deoxygenated C-glycosides as LpxC inhibitors.
Dreger A; Hoff K; Agoglitta O; Bülbül EF; Melesina J; Sippl W; Holl R
Bioorg Chem; 2021 Dec; 117():105403. PubMed ID: 34758434
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors.
Wimmer S; Hoff K; Martin B; Grewer M; Denni L; Lascorz Massanet R; Raimondi MV; Bülbül EF; Melesina J; Hotop SK; Haupenthal J; Rohde H; Heisig P; Hirsch AKH; Brönstrup M; Sippl W; Holl R
Bioorg Chem; 2023 Feb; 131():106331. PubMed ID: 36587505
[TBL] [Abstract][Full Text] [Related]
5. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
[TBL] [Abstract][Full Text] [Related]
6. High-throughput catch-and-release synthesis of oxazoline hydroxamates. Structure-activity relationships in novel inhibitors of Escherichia coli LpxC: in vitro enzyme inhibition and antibacterial properties.
Pirrung MC; Tumey LN; McClerren AL; Raetz CR
J Am Chem Soc; 2003 Feb; 125(6):1575-86. PubMed ID: 12568618
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA
Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of triazolyl-substituted benzyloxyacetohydroxamic acids as LpxC inhibitors.
Hoff K; Mielniczuk S; Agoglitta O; Iorio MT; Caldara M; Bülbül EF; Melesina J; Sippl W; Holl R
Bioorg Med Chem; 2020 Jul; 28(13):115529. PubMed ID: 32386952
[TBL] [Abstract][Full Text] [Related]
9. Chiral pool synthesis and biological evaluation of C-furanosidic and acyclic LpxC inhibitors.
Müller H; Gabrielli V; Agoglitta O; Holl R
Eur J Med Chem; 2016 Mar; 110():340-75. PubMed ID: 26866455
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of xylose-derived LpxC inhibitors - Synthesis, biological evaluation and molecular docking studies.
Dreger A; Hoff K; Agoglitta O; Hotop SK; Brönstrup M; Heisig P; Kirchmair J; Holl R
Bioorg Chem; 2021 Feb; 107():104603. PubMed ID: 33429229
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of flexible and conformationally constrained LpxC inhibitors.
Löppenberg M; Müller H; Pulina C; Oddo A; Teese M; Jose J; Holl R
Org Biomol Chem; 2013 Sep; 11(36):6056-70. PubMed ID: 23917427
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of enantiomerically pure glyceric acid derivatives as LpxC inhibitors.
Tangherlini G; Torregrossa T; Agoglitta O; Köhler J; Melesina J; Sippl W; Holl R
Bioorg Med Chem; 2016 Mar; 24(5):1032-44. PubMed ID: 26827141
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
[TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
17. Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity.
Yamada Y; Takashima H; Walmsley DL; Ushiyama F; Matsuda Y; Kanazawa H; Yamaguchi-Sasaki T; Tanaka-Yamamoto N; Yamagishi J; Kurimoto-Tsuruta R; Ogata Y; Ohtake N; Angove H; Baker L; Harris R; Macias A; Robertson A; Surgenor A; Watanabe H; Nakano K; Mima M; Iwamoto K; Okada A; Takata I; Hitaka K; Tanaka A; Fujita K; Sugiyama H; Hubbard RE
J Med Chem; 2020 Dec; 63(23):14805-14820. PubMed ID: 33210531
[TBL] [Abstract][Full Text] [Related]
18. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
19. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T
Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863
[TBL] [Abstract][Full Text] [Related]
20. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
